Several classes of therapy can substitute for or reduce dependence on intravenous immunoglobulin (IVIG), depending on the disease being treated and the reason a switch is needed. Options range from subcutaneous immunoglobulin, which delivers the same antibodies through a different route, to newer targeted drugs like FcRn inhibitors that lower harmful antibodies without using pooled human plasma at all. The best alternative for any individual depends on diagnosis, disease severity, and practical factors like cost, infusion access, and tolerability.
Why the Search for Alternatives Keeps Growing
IVIG is manufactured from pooled human plasma, and the global supply chain for that plasma is fragile. Roughly 70 percent of the world’s plasma comes from the United States, and manufacturing immunoglobulin from raw plasma takes 7 to 12 months, far longer than the 2 to 3 months typical for other biologic drugs.1PubMed Central. Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages During the COVID-19 pandemic, plasma collection in the United States dropped by about 18 percent, and global collection fell by roughly 15 percent.2Frontiers in Pharmacology. Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy These supply disruptions are not one-off events. Demand for immunoglobulin therapy has been rising steadily as more autoimmune and inflammatory conditions gain evidence for IVIG treatment, so the gap between supply and demand only widens over time.
For patients, this translates into delayed infusions, dose rationing, and sometimes abrupt therapy interruptions. Clinicians, meanwhile, face pressure to reserve IVIG for the indications where no good substitute exists. That practical reality is what makes the landscape of alternatives so important to understand.
Subcutaneous Immunoglobulin
The simplest switch from IVIG is subcutaneous immunoglobulin (SCIG). The product is essentially the same concentrated human antibody, just delivered through a small needle under the skin rather than into a vein. You can do it at home, usually weekly or biweekly, and each session takes anywhere from about 30 minutes to a couple of hours depending on the volume and infusion device.
A systematic review and meta-analysis comparing IVIG and SCIG for primary immunodeficiency found no statistically significant difference in the risk of overall infections or serious infections between the two routes.3PubMed Central. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies SCIG actually produced higher average trough antibody levels than monthly IVIG, which makes sense because smaller, more frequent doses avoid the steep peaks and valleys of once-a-month infusions. The trade-off is that SCIG does not solve the plasma supply problem since it still uses pooled human immunoglobulin. It does, however, free up hospital infusion chairs and can significantly improve quality of life for people who tolerate home infusions well.
Plasma Exchange and Immunoadsorption
Therapeutic plasma exchange (sometimes called plasmapheresis) physically removes a patient’s plasma and replaces it with albumin or donor plasma. Because the removed plasma carries the harmful autoantibodies, the technique can produce rapid improvement in acute crises, particularly in neurologic autoimmune diseases like myasthenia gravis and Guillain-Barré syndrome. Immunoadsorption is a more selective version. Instead of swapping out all the plasma, it passes the patient’s blood through a column that binds and removes immunoglobulins, then returns the cleaned plasma to the body.
Both procedures work and are considered safe for neurologic autoimmune conditions, but immunoadsorption appears to have an edge in durability. One analysis noted a trend toward longer-lasting treatment responses in immunoadsorption-treated patients compared to plasma exchange, possibly because immunoadsorption also lowered levels of certain pro-inflammatory signaling molecules that plasma exchange left untouched.4PubMed. Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases In clinical practice, immunoadsorption has been steadily replacing standard plasma exchange for some neurologic indications because it offers similar antibody removal with a better safety profile, avoiding the loss of clotting factors and other plasma proteins that get discarded during a full plasma exchange.5Atherosclerosis Supplements. Plasma exchange and immunoadsorption for autoimmune neurologic diseases – current guidelines and future perspectives
Both approaches require specialized equipment and vascular access, which limits them mainly to hospital or specialized outpatient settings. They are most useful for fast rescue therapy during disease flares rather than long-term maintenance.
Corticosteroids and Pulse Steroid Therapy
High-dose intravenous corticosteroids remain one of the most accessible and widely used alternatives to IVIG, especially in settings where immunoglobulin supply is limited or costs are prohibitive. Pulse steroid therapy, which involves giving very high doses over a few days, is used across a range of autoimmune conditions in both adults and children, including rapidly progressive kidney inflammation, systemic lupus, vasculitis, multiple sclerosis relapses, and severe juvenile arthritis.6PubMed. Pulse steroid therapy
Steroids are not universally interchangeable with IVIG, though. In severe autoimmune thrombocytopenia (where the immune system destroys platelets), a randomized trial found that IVIG combined with oral prednisone was more effective than high-dose intravenous methylprednisolone plus oral prednisone, although the steroid-only approach still worked and was well tolerated.7The Lancet. Intravenous immunoglobulin versus high-dose methylprednisolone: a multicentre randomised trial in adults with severe autoimmune thrombocytopenic purpura For chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks the nerves’ insulating coating, about 60 percent of patients responded to corticosteroid therapy regardless of whether they received daily prednisolone, pulsed dexamethasone, or pulsed intravenous methylprednisolone, and over half of responders maintained remission for at least five years.8PubMed Central. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone
The main downside of steroids is that long-term use brings well-known side effects: weight gain, bone thinning, high blood sugar, mood changes, and increased infection risk. Pulse dosing partly mitigates this by reducing cumulative exposure, but steroids are best thought of as a bridge or a first-line treatment for conditions where they work, not as a permanent replacement for IVIG in diseases that demand ongoing immunomodulation.
Conventional Immunosuppressants as Steroid-Sparing Agents
Drugs like mycophenolate mofetil, azathioprine, and cyclosporine dampen the immune system broadly and are often used as “steroid-sparing” agents, meaning they allow clinicians to taper steroids without the disease flaring back. They can also reduce or replace IVIG in certain conditions. In treatment-resistant CIDP, for example, adding mycophenolate led to measurable improvements in muscle strength and disability scores, and patients were able to reduce their IVIG doses and spend fewer days per month in an infusion center.9PubMed. Mycophenolate Facilitates Improvement in Outcome Measures in Treatment Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy
These drugs take weeks to months to reach full effect, so they are not useful for acute crises. They also carry risks of infection and, in some cases, require regular blood monitoring. Their role in the IVIG alternative landscape is primarily as long-term maintenance therapy that can lower dependence on immunoglobulin infusions for chronic autoimmune conditions.
FcRn Inhibitors
This is where the alternative landscape has changed most dramatically in recent years. FcRn (neonatal Fc receptor) inhibitors work by blocking a receptor that normally recycles IgG antibodies and extends their lifespan in the bloodstream. By disrupting that recycling, these drugs accelerate the breakdown of circulating IgG, including the pathogenic autoantibodies driving disease, without broadly suppressing the immune system’s other components.10PubMed Central. FcRn Inhibition in Autoantibody-Mediated Autoimmune Diseases: From Broad Immunosuppression to Precision IgG Modulation
Two FcRn inhibitors, efgartigimod and rozanolixizumab, have drawn the most clinical attention. In generalized myasthenia gravis, an indirect comparison found that both doses of rozanolixizumab significantly outperformed IVIG on a standard muscle weakness score at two and four weeks.11PubMed. Comparative Efficacy of Rozanolixizumab with Efgartigimod or Intravenous Immunoglobulin in Generalized Myasthenia Gravis Using Matching Adjusted Indirect Comparisons Research on efgartigimod has also revealed that the drug does more than just lower IgG levels. In patients with myasthenia gravis, treatment triggered an increase in memory B cells and plasma cells that appeared to be non-pathogenic and even regulatory, suggesting the drug may reshape immune responses rather than simply depleting antibodies.12PubMed Central. Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis A New Mechanism of Action Beyond IgG Reduction
FcRn inhibitors are especially appealing because they do not depend on human plasma. They are manufactured as recombinant biologics, so their supply is not constrained by plasma collection. Their main limitation right now is a narrow range of approved indications, though clinical trials are expanding into other antibody-driven diseases.
B-Cell Depleting Therapies
Rituximab, a monoclonal antibody that targets the CD20 protein on B cells and wipes out the cells that produce autoantibodies, has become one of the most commonly used alternatives to IVIG across a wide range of autoimmune diseases. A systematic review specifically examining rituximab as a potential substitute for IVIG found that it has immune-modulatory effects similar to IVIG for many conditions.13PubMed. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin
Rituximab is particularly useful in diseases where IVIG performs poorly. Some neurologic autoimmune diseases are driven by IgG4-type antibodies, a subclass that does not respond well to IVIG because of the way IgG4 antibodies interact with immune receptors. For those conditions, B-cell depleting therapies that eliminate the source of the problem tend to produce longer-lasting benefits.14PubMed Central. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies The dosing schedule also favors patient convenience: rituximab is typically given as one or two infusions every several months, rather than the recurring monthly cycles of IVIG.
The risk profile is different, though. Depleting B cells can lead to prolonged low antibody levels (hypogammaglobulinemia), delayed immune recovery, and increased susceptibility to certain infections. These effects are generally manageable but mean that rituximab is best suited to patients whose disease is severe enough to justify the immune trade-off.
Anti-Complement Therapies
In diseases driven by an overactive complement system, the part of the immune system that punches holes in cells flagged for destruction, complement inhibitors offer a targeted alternative. Eculizumab, a monoclonal antibody that blocks complement component C5, transformed outcomes for patients with atypical hemolytic uremic syndrome, restoring life expectancy close to that of the general population. The longer-acting C5 inhibitor ravulizumab has since expanded treatment options by allowing less frequent dosing.15PubMed Central. Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany
Complement inhibitors are not a broad IVIG replacement. They are condition-specific, most relevant for diseases like atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and certain forms of myasthenia gravis where complement-mediated damage is a central driver. But for those diseases, they can be far more effective than IVIG and are manufactured as recombinant proteins independent of plasma supply.
BTK Inhibitors
Bruton’s tyrosine kinase (BTK) inhibitors represent a newer class of oral drugs being tested in autoimmune settings. Rilzabrutinib, one of the lead candidates, works through two mechanisms: it reduces the ability of immune cells called macrophages to destroy platelets, and it suppresses the production of pathogenic autoantibodies.16PubMed. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia Clinical trials in immune thrombocytopenia have shown that BTK inhibitors can stabilize platelet counts with a favorable safety profile.17PubMed Central. Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence
The appeal of BTK inhibitors is largely practical: they are pills, not infusions. If they prove effective in broader autoimmune conditions, they could relieve pressure on infusion infrastructure and immunoglobulin supplies simultaneously. They remain investigational for most autoimmune indications, but their development is one of the more closely watched areas in the field.
Plasma Cell Targeted Therapies
When autoantibody-producing plasma cells are the root problem and other therapies have failed, daratumumab, an anti-CD38 antibody originally developed for multiple myeloma, has emerged as a last-resort option. A systematic review covering 83 patients across 24 different autoimmune diseases found that these were deeply treatment-resistant cases, with a median of five different prior therapies having failed. Despite that, about 81 percent of patients showed remission or improvement, and autoantibody levels dropped in roughly half.18PubMed Central. Daratumumab for autoimmune diseases: a systematic review Adverse events were common, with about a third developing low antibody levels and around a fifth experiencing infusion reactions, so daratumumab is not a first-line therapy by any stretch. But for patients who have exhausted standard options including IVIG, it represents a meaningful salvage strategy.
Recombinant Alternatives in Development
One of the holy grails in this space is a synthetic product that can replicate the anti-inflammatory effects of IVIG without needing human plasma at all. Research into recombinant Fc multimers, engineered proteins that mimic the active fraction of IVIG responsible for its immune-calming effects, is still in early stages but shows promise. One such molecule, GL-2045, was designed to replicate IVIG’s anti-inflammatory and tolerogenic properties using a recombinant human IgG1 Fc multimer. Preclinical work demonstrated immunomodulatory activity consistent with that goal.19PubMed Central. A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity
If recombinant alternatives eventually reach the clinic, they would address the core supply problem head-on. Manufacturing could be scaled like any other biologic drug, with production timelines measured in months rather than the better part of a year. Researchers have also noted that identifying specific antibody profiles within IVIG lots that drive efficacy could open the door to more personalized treatment, matching specific immunoglobulin preparations to individual patients’ disease biology.20Frontiers in Immunology. Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
The Cost Picture Is Complicated
IVIG is expensive, sometimes staggeringly so. Whether alternatives are cheaper depends entirely on the disease and the alternative in question, and the evidence points in different directions depending on the condition. In myasthenia gravis, a Canadian cost-effectiveness analysis found that efgartigimod was predicted to save roughly $257,000 over a lifetime compared to chronic immunoglobulin therapy while also delivering better quality-adjusted life years.21Canadian Journal of Neurological Sciences. Cost-Effectiveness Analysis of Efgartigimod vs Chronic Immunoglobulin for the Treatment of Myasthenia Gravis in Canada Japanese post-marketing surveillance data, on the other hand, found that IVIG was substantially more cost-effective per unit of clinical improvement than newer molecular targeted drugs for generalized myasthenia gravis.22Journal of Autoimmunity. Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance
In CIDP, the gap can be even more striking. A cost comparison between IVIG and subcutaneous efgartigimod found that at 12 months, IVIG cost per responder ranged from roughly $257,000 to $473,000 depending on the dose, while the per-responder cost for subcutaneous efgartigimod exceeded $1.4 million, driven partly by its lower response rate in that disease.23PubMed. Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy The lesson is that newer does not automatically mean better value, and the cost calculus shifts dramatically depending on the condition, the country’s pricing structure, and whether you measure cost per course or cost per clinical response.
Pregnancy and Pediatric Considerations
IVIG is one of the few immunomodulatory therapies considered relatively safe during pregnancy, which creates a challenge when alternatives are needed. Rituximab, for instance, crosses the placenta, and while a clinical review found no consistent association between rituximab exposure and congenital anomalies, neonatal B-cell depletion has been reported, even if it appears to be transient.24Wolters Kluwer Health / International Journal of Women’s Dermatology. Rituximab for autoimmune blistering diseases in pregnancy and children: a clinical review The safest window for rituximab in pregnancy appears to be preconception or early in gestation, well before significant placental transfer occurs.
In children, rituximab shows promising efficacy for conditions like autoimmune blistering diseases, but concerns about prolonged low antibody levels and slow immune recovery are amplified because pediatric immune systems are still developing. Most FcRn inhibitors and BTK inhibitors have not been extensively studied in children or pregnant women, so IVIG and corticosteroids often remain the default choices in these populations simply because the safety data for alternatives is thin. For clinicians managing autoimmune disease during pregnancy or in young children, the practical alternative to IVIG is usually SCIG or carefully timed steroid pulses rather than the newer targeted agents.
How Clinicians Choose Among These Options
No single alternative replaces IVIG across all its uses. In practice, the choice depends on a few key factors. Speed of onset matters: plasma exchange and high-dose steroids work within days, while mycophenolate takes months. Route of delivery matters: oral BTK inhibitors and home-based SCIG are far more convenient than hospital-based plasma exchange. The underlying disease mechanism matters most of all: if the disease is driven by complement, complement inhibitors are the logical target; if it is driven by IgG4 autoantibodies, B-cell depletion has an advantage over IVIG itself.
The field is moving toward stacking therapies rather than swapping one for another wholesale. A patient with CIDP might receive IVIG for initial disease control, add mycophenolate as a steroid-sparing maintenance agent, and eventually transition to an FcRn inhibitor once the disease stabilizes. A patient with severe myasthenia gravis in crisis might get plasma exchange for rapid stabilization, followed by rituximab to prevent the next flare, with an FcRn inhibitor considered if antibody levels remain problematic. The era of IVIG-or-nothing is ending, but what replaces it is not a single drug but a menu that clinicians mix and sequence based on each patient’s trajectory.